INBP INTEGRATED BIOPHARMA INC
Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%
Returns
ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.91M | $9.80M | $10.11M | $11.28M | $12.69M | $14.18M | $13.95M | $12.61M |
| Cost of revenue | $10.03M | $9.77M | $10.38M | $11.25M | $11.67M | $12.71M | $12.40M | $11.44M |
| Gross profit | -$112,000 | $28,000 | -$276,000 | $29,000 | $1.02M | $1.47M | $1.55M | $1.17M |
| SG&A expense | $849,000 | $897,000 | $809,000 | $943,000 | $856,000 | $880,000 | $812,000 | $969,000 |
| Operating income | -$961,000 | -$869,000 | -$1.08M | -$914,000 | $163,000 | $589,000 | $739,000 | $202,000 |
| Interest expense | — | $124,000 | -$39,000 | -$40,000 | -$33,000 | $76,000 | -$5,000 | -$11,000 |
| Pretax income | -$923,000 | -$850,000 | -$1.03M | -$874,000 | $196,000 | $595,000 | $778,000 | $185,000 |
| Income tax | -$232,000 | $516,000 | -$198,000 | -$112,000 | $73,000 | $773,000 | $167,000 | $69,000 |
| Net income | -$691,000 | -$1.37M | -$837,000 | -$762,000 | $123,000 | -$178,000 | $611,000 | $116,000 |
| EBITDA | -$894,000 | -$799,000 | -$1.02M | -$836,000 | $240,000 | $660,000 | $815,000 | $285,000 |
| EPS (basic) | -0.02 | — | -0.03 | -0.03 | 0.00 | — | 0.02 | 0.00 |
| EPS (diluted) | -0.02 | — | -0.03 | -0.03 | 0.00 | — | 0.02 | 0.01 |
| Weighted avg. shares (diluted) | 31.06M | — | 31.06M | 31.06M | 31.42M | — | 31.51M | 31.30M |
| Balance sheet | ||||||||
| Cash & equivalents | $3.12M | $4.47M | $5.83M | $5.31M | $4.73M | $3.62M | $2.96M | $2.46M |
| Receivables | $3.72M | $3.33M | $3.65M | $3.59M | $3.98M | $5.43M | $5.08M | $4.23M |
| Inventory | $8.54M | $9.14M | $8.12M | $8.36M | $10.47M | $9.36M | $10.08M | $11.07M |
| Current assets | $15.98M | $17.38M | $17.97M | $17.82M | $19.62M | $18.76M | $18.55M | $18.15M |
| PP&E, net | $1.81M | $1.75M | $1.70M | $1.76M | $1.82M | $1.72M | $1.81M | $1.77M |
| Total assets | $24.03M | $25.34M | $26.67M | $23.55M | $25.54M | $24.90M | $25.66M | $25.66M |
| Current liabilities | $5.45M | $5.80M | $5.53M | $3.54M | $4.76M | $4.25M | $4.98M | $5.58M |
| Total liabilities | $7.01M | $7.67M | $7.69M | $3.78M | $5.05M | $4.58M | $5.27M | $5.93M |
| Shareholders' equity | $17.02M | $17.67M | $18.98M | $19.77M | $20.49M | $20.32M | $20.38M | $19,727 |
| Shares outstanding | 31.09M | 31.06M | 31.09M | 31.09M | 31.06M | 31.06M | 30.30M | 30.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.22M | -$1.19M | $517,000 | $617,000 | $1.30M | $591,000 | $616,000 | $201,000 |
| Capital expenditure | $124,000 | $149,000 | $0 | $24,000 | $173,000 | -$10,000 | $116,000 | $29,000 |
| Free cash flow | -$1.34M | -$1.34M | $517,000 | $593,000 | $1.13M | $601,000 | $500,000 | $172,000 |
| Investing cash flow | -$124,000 | -$149,000 | $6,000 | -$24,000 | -$173,000 | -$4,000 | -$116,000 | -$29,000 |
| Financing cash flow | -$12,000 | -$12,000 | -$11,000 | -$11,000 | -$11,000 | $67,000 | $0 | $18,000 |
| Depreciation & amortization | $67,000 | $70,000 | $68,000 | $78,000 | $77,000 | $71,000 | $76,000 | $83,000 |
| Stock-based compensation | $39,000 | $51,000 | $50,000 | $42,000 | $49,000 | $44,000 | $45,000 | $43,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.